Welcome to our dedicated page for Medpace Holdings SEC filings (Ticker: MEDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Medpace Holdings, Inc. (Nasdaq: MEDP), a scientifically driven, global, full-service clinical contract research organization (CRO). Through these filings, investors can review the company’s official financial statements, risk disclosures, material agreements and other regulatory information that frame analysis of MEDP stock.
Medpace’s SEC reporting includes annual reports on Form 10-K, which contain audited financial statements, management’s discussion and analysis, and a detailed “Risk Factors” section describing uncertainties such as contract loss, backlog conversion, pricing pressure, international operations, regulatory compliance, and information systems risks. Quarterly reports on Form 10-Q provide interim financial updates and additional context on operating performance in the clinical research and development services business.
The company also files current reports on Form 8-K to disclose specific events. For example, Medpace has used Form 8-K to furnish earnings press releases under Item 2.02 and to describe amendments to its unsecured credit facility under Item 1.01, including changes to the aggregate principal amount available under its line of credit. These filings give detail on financing arrangements and other material developments beyond the headline numbers in press releases.
On Stock Titan, Medpace filings are paired with AI-powered summaries that highlight key points from lengthy documents, such as major changes in revenue and profitability, updates to guidance, or notable shifts in risk disclosures. Users can quickly scan 10-K and 10-Q reports, as well as 8-K items, while retaining the option to open the full SEC documents for deeper review. This page also surfaces information relevant to tracking management decisions, capital structure, and other regulatory matters that influence Medpace’s long-term profile as a global CRO.
Medpace Holdings, Inc. General Counsel & Corporate Secretary Stephen P. Ewald exercised employee stock options for 3,500 shares on February 17, 2026. This option exercise converted into 3,500 shares of common stock at $138.87 per share. Following the transactions, he directly held 16,843 shares of common stock and 19,849 derivative securities.
The option referenced in the filing vested in full on February 15, 2026.
Medpace Holdings director Brian T. Carley exercised stock options to acquire 6,472 shares of common stock at $54.99 per share on 02/13/2026. Following this option exercise, he directly owned 32,753 shares of Medpace common stock. The exercised option had vested in full on May 14, 2020 and is now fully exhausted, with no derivative securities remaining from this grant.
Medpace Holdings, Inc. executive Susan E. Burwig exercised stock options to acquire 10,984 common shares on February 13, 2026. The options, with an exercise price of $107.93 per share, were fully vested as of February 28, 2020. Following the transaction, she directly owns 58,484 Medpace common shares. The exercised employee stock option derivative position is now fully exhausted, with zero derivative securities remaining.
Medpace Holdings, Inc. is a global, full-service clinical contract research organization focused on Phase I–IV drug, biologic and medical device development. It provides integrated services from study design and feasibility through monitoring, labs, data science, pharmacovigilance and regulatory submissions across major therapeutic areas, especially oncology, metabolic disease, cardiology, AVAI and CNS.
The company serves a diversified base of small and mid-sized biopharmaceutical customers, with 82% of 2025 net revenue from small biopharma and 13% from mid-sized companies. Medpace reports approximately 6,200 employees across 46 countries and 28,381,283 common shares outstanding as of February 6, 2026, with non‑affiliate equity valued at about $7.0 billion as of June 30, 2025.
The filing highlights extensive risk factors, including contract cancellations, backlog conversion uncertainty, pricing pressure on margins, customer and therapeutic concentration, reliance on third-party vendors, evolving AI tools, cybersecurity threats to systems such as ClinTrak, global regulatory and anti‑corruption exposure, healthcare reform, and environmental, social and governance expectations.
Medpace Holdings reported strong growth for the fourth quarter and full year 2025 and issued upbeat 2026 guidance. Fourth quarter 2025 revenue rose 32.0% to $708.5 million, with net income of $135.1 million, or $4.67 per diluted share, and a net book-to-bill ratio of 1.04x. Backlog reached $3,027.2 million at year-end.
For full year 2025, revenue grew 20.0% to $2,530.2 million and GAAP net income increased to $451.1 million, or $15.28 per diluted share, though net income margin eased to 17.8%. EBITDA was $557.7 million with a 22.0% margin.
Medpace generated $713.2 million in operating cash flow in 2025 and repurchased 2,961,924 shares for $912.9 million, ending the year with $497.0 million in cash and $821.7 million remaining under its repurchase authorization. For 2026, the company projects revenue of $2.755–$2.855 billion, GAAP net income of $487.0–$511.0 million, EBITDA of $605.0–$635.0 million, and diluted EPS of $16.68–$17.50.
Medpace Holdings, Inc. (MEDP) CEO August J. Troendle, who is also a director and 10% owner, reported open-market sales of Medpace common stock. On 11/24/2025, he sold 59,025 shares at a weighted average price of $607.78 per share, and on 11/25/2025 he sold 42,392 shares at a weighted average price of $615.52 per share. After these transactions, he directly beneficially owns 774,602 shares and indirectly beneficially owns 4,733,019 shares through Medpace Investors, LLC, over which he has voting and investment control and for which he disclaims beneficial ownership beyond his economic interest.
Medpace Holdings, Inc. executive reports stock sale
A Medpace Holdings, Inc. executive vice president of operations filed a Form 4 reporting the sale of 20,000 shares of Medpace common stock on 11/24/2025. The shares were sold at a weighted average price of $609.15 per share, through multiple trades within a price range of $607.59 to $610.92, executed under a pre-placed limit order during an open trading window. Following this transaction, the reporting person directly holds 27,500 shares of Medpace common stock.
Medpace Holdings, Inc. (MEDP) reported insider activity by its CFO & Treasurer, Kevin M. Brady. On 11/21/2025, he exercised an employee stock option for 3,000 shares of common stock at an exercise price of $166.73 per share, increasing his holdings, then sold 3,000 shares of common stock in a market transaction coded as a sale. The reported sale price is a weighted average of $590.35 per share, based on multiple trades between $590.00 and $590.72 placed via a limit order during an open trading window.
On the same date, Brady also gifted 170 shares of common stock to a donor-advised fund. After these transactions, he directly beneficially owned 5,830 shares of Medpace common stock. The employee stock option for 3,000 shares, which had vested in full on October 27, 2025, was fully exercised and no longer outstanding following the reported activity.
Medpace Holdings, Inc. (MEDP) CEO, director and 10% owner August J. Troendle reported open‑market sales of Medpace common stock. On 11/20/2025 he sold 6,830 shares at a weighted average price of $598.49, with individual trades ranging from $590.00 to $604.23. On 11/21/2025 he sold 21,858 shares at a weighted average price of $592.18, with trades ranging from $590.00 to $595.58. The transactions were effected under a limit order placed during an open window period. Following these sales, he directly beneficially owns 833,627 shares and indirectly beneficially owns 4,733,019 shares through Medpace Investors, LLC, where he has sole voting and investment control and may be deemed to beneficially own those securities to the extent of his pecuniary interest.
Medpace Holdings, Inc. (MEDP) CEO, director and 10% owner August J. Troendle reported selling common stock in two transactions in November 2025. On November 18, 2025, he sold 7,191 shares at a weighted average price of $590.84, leaving 886,177 shares owned directly. On November 19, 2025, he sold an additional 23,862 shares at a weighted average price of $592.07, leaving 862,315 shares owned directly.
The filing notes these trades were executed under a limit order during an open trading window and that prices reflect multiple trades within disclosed ranges. Troendle also reports indirect beneficial ownership of 4,733,019 shares held by Medpace Investors, LLC, where he is the sole manager and controlling unitholder, while formally disclaiming beneficial ownership beyond his economic interest.